E-Mail Updates

Click here to join
our Electronic Communications.

Investors & Media

Whats new.

Press releases

Press releases.

Immutep Receives A$1.9 Million Research and Development Related Tax Rebate from French Government

August 21st 2018
press releases

Immutep to Present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference

August 16th 2018
press releases

Immutep Secures Canadian Patent Grant for IMP731 Antibody

August 7th 2018
press releases

Investor updates

Investor updates.

Investor Update - June 2018

June 19th 2018
investor updates

Investor Update - December 2017

December 21st 2017
investor updates

Investor Update Edition 21

October 1st 2017
investor updates

Analyst reports

Analyst reports.

Maxim – Pipeline Update: Eftilagimod Moves Forward, Partners are Busy - Novartis, GSK, EOC (China)

August 8th 2018
analyst reports

Maxim – First US-Based Study of IMP321 Gets Green Light from FDA, Initiating 2H18

July 31st 2018
analyst reports

Maxim – Reports June Quarter: Cash Runway Through Several Data Points in the LAG-3 Pipeline

July 30th 2018
analyst reports